Drugs / KRAS peptide vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05013216 | Apr 2022 → Oct 2027 expected | hereditary neoplastic syndrome, malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04117087 | May 2020 → Jun 2027 expected | colorectal cancer, malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KRAS peptide vaccine | “Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC” NCT05013216 ↗ |
| Known as | pooled mutant-KRAS peptide vaccine | “This study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant.” NCT05013216 ↗ |
| Modality | Vaccine | “pooled synthetic long peptide vaccine targeting the six KRAS mutations” PMID 41667470 ↗ Feb 2026 |
| Target | KRAS | “pooled synthetic long peptide vaccine targeting the six KRAS mutations” PMID 41667470 ↗ Feb 2026 |